Jan W. Gratama

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

C. B. H. W. Lamers, Stefan Sleijfer, Sabine van Steenbergen et al. · Molecular Therapy · 2013 · 709 citations · Full text

Medicine, Immunology, Oncology +17

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

Monique Terwijn, Wim L.J. van Putten, Angèle Kelder et al. · Journal of Clinical Oncology · 2013 · 449 citations · Full text

Medicine, Hematology, Oncology +16

Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

Joost W. J. van Esser, Hubert G.M. Niesters, Bronno van der Holt et al. · Blood · 2002 · 401 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell–depleted SCT

Joost W. J. van Esser, Bronno van der Holt, Ellen Meijer et al. · Blood · 2001 · 371 citations · Full text

Medicine, Hematology, Immunology +14

Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells

C. B. H. W. Lamers, Ralph A. Willemsen, Pascal van Elzakker et al. · Blood · 2010 · 367 citations · Full text

Life Sciences, Immunology, Translational Sciences +16